This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
Semaglutide B will be administered subcutaneously.
Semaglutide J will be administered as oral tablets.
Semaglutide L will be administered as oral tablets.
Altasciences
Montreal, Quebec, Canada
Adjusted AUC(sema); adjusted area under the semaglutide plasma concentration-time curve
Measured in hours nanomoles per liter (h \* nmol/L).
Time frame: From 0 to 24 hours after dosing on Days 122 and 132.
Adjusted Cmax,(sema); adjusted maximum observed semaglutide plasma concentration
Measured in nanomoles per liter(nmol/L).
Time frame: From 0 to 24 hours after dosing on Days 122 and 132.
Adjusted tmax,sema; time to adjusted maximum observed semaglutide plasma concentration
Measured in hours.
Time frame: From 0 to 24 hours after dosing on Days 122 and 132.
t½,sema; the terminal half-life of semaglutide
Measured in hours.
Time frame: From 0 to 840 hours after dosing on Day 132.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Semaglutide M will be administered as oral tablets.
Semaglutide N will be administered as oral tablets.